Advertisement

Topics

Latest "Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Iodinated Activated Charcoal" News Stories

15:47 EDT 18th March 2019 | BioPortfolio

Here are the most relevant search results for "Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Iodinated Activated Charcoal" found in our extensive news archives from over 250 global news sources.

More Information about Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Iodinated Activated Charcoal on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Iodinated Activated Charcoal for you to read. Along with our medical data and news we also list Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Iodinated Activated Charcoal Clinical Trials, which are updated daily. BioPortfolio also has a large database of Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Iodinated Activated Charcoal Companies for you to search.

Showing "Treatment Chronic Obstructive Pulmonary Disease COPD With Iodinated" News Articles 1–25 of 29,000+

Monday 18th March 2019

Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting

Oral Plenary Presentation Receives SGO Presidential Award Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced today that updated results from the cervical cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the efficacy of neratinib in HER2-mutated cancers, were reported at the Society of Gynecologic Oncology...


Vida Health Launches Habits to Support Behavior Change in Personalized Programs

Vida combines machine learning and behavior change techniques to drive engagement and improve population health through day-to-day habits SAN FRANCISCO (PRWEB) March 18, 2019 Vida Health, a personalized virtual care platform for physical and behavioral health, today announced the launch of Habits, a machine-learning driven experience that delivers personalized recommendations and reminders. Along...

Latest Research Continues to Validate the Etiometry Platform’s Impact on Critical Care

The American College of Cardiology Conference unveiled a first-of-its kind study evaluating the effect of a digital health platform based on registry data. The abstract presented by Dr. Mary K. Olive, Pediatric Cardiac Critical Care Physician at C.S. Mott Children’s Hospital, is now a part of the growing evidence associating Etiometry’s...


Children's Noses Hold Clues to Serious Lung Infections

NewsTiny organisms in a child's nose could offer clues to improving the diagnosis and treatment of severe lung infections.

Dr. Jonathan Zaidan of Women's Excellence Promotes Excision of Endometriosis for Endometriosis Awareness Month

Dr. Jonathan Zaidan is the #1 robotic surgeon for excision of endometriosis in the Midwest. DETROIT (PRWEB) March 18, 2019 Dr. Jonathan Zaidan, MD, FACOG, President of Women’s Excellence discusses excision of endometriosis in recent blog post at https://www.womensexcellence.com/blog/excision-endometriosis-treatment-2/. In addition, Dr. Zaidan has published pathology reports to educate women o...

The Philadelphia Adult Congenital Heart Center Earns Accreditation from the Adult Congenital Heart Association (ACHA)

Joint program between Children’s Hospital of Philadelphia and Penn Medicine is the first Delaware Valley institution to have earned ACHA Adult Congenital Heart Disease (ACHD) Accreditation MEDIA, Pa. (PRWEB) March 18, 2019 In recognition of its expertise in serving adults with congenital heart disease (CHD), the Philadelphia Adult Congenital Heart Center has received accreditation from the Adul...

Daiichi Sankyo show positive results for atrial fibrillation treatment Lixiana (edoxoban) http://bit.ly/2Y7Hn0f  @EUdaiichisankyo #pharmapic.twitter.com/rO5PBNNyUt

Daiichi Sankyo show positive results for atrial fibrillation treatment Lixiana (edoxoban) http://bit.ly/2Y7Hn0f  @EUdaiichisankyo #pharma pic.twitter.com/rO5PBNNyUt

Daiichi Sankyo show positive results for atrial fibrillation treatment Lixiana (edoxoban)

Japanese firm Daiichi Sankyo has announced positive results of the first randomised controlled trial of uninterrupted Lixiana (edoxoban) in atrial fibrillation patients undergoing catheter ablation. The study showed the uninterrupted anticoagulation regimen with 60mg edoxaban versus uninterrupted vitamin K antagonists, in patients undergoing catheter ablation resulted in low event rates for both t...

Encorafenib/Binimetinib-based Triplet Added to NCCN Guidelines for BRAF+ CRC

The NCCN has updated their clinical practice guidelines for the treatment of patients with colorectal cancer to include the regimen of encorafenib and binimetinib plus EGFR inhibition with either cetuximab or panitumumab as a Category 2a treatment recommendation for patients with BRAF V600E–mutant metastatic colorectal cancer, after failure of 1 or 2 lines of therapy for metastatic disease.

How to detect ovarian cancer earlier

Fewer than half of ovarian cancer patients survive until five years after diagnosis. According to the American Cancer Society, this is because only about one-fifth of ovarian cancer cases are detected early, when the chances of successful treatment and...

GEN Webinar, April 2, 8 am PT / 11 am ET / 1700 CET -- Fibro-Inflammatory Disease Sees Relief in IL-11 mAb Development. Register now at: http://ow.ly/khzv30o5w5N pic.twitter.com/tnkLdmdqWM

GEN Webinar, April 2, 8 am PT / 11 am ET / 1700 CET -- Fibro-Inflammatory Disease Sees Relief in IL-11 mAb Development. Register now at: http://ow.ly/khzv30o5w5N  pic.twitter.com/tnkLdmdqWM

SpinalCyte to Present at China Focus @ Europe Vienna

SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced that Pete O’Heeron, SpinalCyte’s Chief Executive Officer, will present at the China Focus @ Europe Vienna on Wednesday, March 27, 2019 at 3:00 PM CET in Vienna, Austria. In his presentation,...

Transgene Secures a €20 Million Revolving Credit Facility with Natixis

Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases, announces that it has secured a €20 million revolving credit facility with Natixis, the French Corporate and Investment bank. The credit facility will have ...

Usmani Elucidates Management of Early Relapse in Multiple Myeloma

Saad Z. Usmani, MD, shares insight on approaches to early relapse in myeloma given the evolution of frontline treatment advances.

New Study: Over-the-Counter (OTC) Products Used by Millions of Americans Saves Healthcare System Billions Annually

Cost savings from reduced need for clinical visits and prescription drugs due to OTCs saves U.S. health system $146 billion annually Today, the Consumer Healthcare Products Association (CHPA) released a new study, “Value of OTC Medicines to the U.S. Healthcare System,” that found, on average, each dollar spent on over-the-counter (OTC) medicines sa...

Digital Therapeutics: A threat or opportunity to pharmaceuticals

Reporter and Curator: Dr. Sudipta Saha, Ph.D.   Digital Therapeutics (DTx) have been defined by the Digital Therapeutics Alliance (DTA) as “delivering evidence based therapeutic interventions to patients, that are driven by software to prevent, manage or treat a medical disorder or disease”. They might come in the form of a smart phone or computer […]

Biohaven Secures a Priority Review Voucher for its Rimegepant Zydis for Treatment of Migraine

NEW HAVEN, Conn., March 18, 2019 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders, today announced that the company has purchased a U.S. Food and Drug Administration (FDA...

A Restorative Skin Cream May Reduce Inflammaging

The

HAEMATO AG: Preliminary Results 2018

DGAP-News: HAEMATO AG / Key word(s): Preliminary Results 18.03.2019 / 15:14 The issuer is solely responsible for the content of this announcement. Corporate News of HAEMATO AG: HAEMATO AG was able to achieve an EBITDA of EUR 10.0m for the fiscal year 2018 according to preliminary IFRS financial statements. HAEMATO AG, Berlin (ISIN: DE0006190705), achieved consolidated sales of EUR 27...

News & Views: A small molecule that forms cell-membrane pores allowing ion transport shows therapeutic promise in human cells from people with cystic fibrosis and an animal model of the disease, reports a Nature paper. https://go.nature.com/2UDN0kW 

News & Views: A small molecule that forms cell-membrane pores allowing ion transport shows therapeutic promise in human cells from people with cystic fibrosis and an animal model of the disease, reports a Nature paper. https://go.nature.com/2UDN0kW 

Catheter ablation for atrial fibrillation no better than drug therapy for reducing death or disabling stroke, trial finds

Catheter ablation achieved no significant reduction in death, disabling stroke, serious bleeding, or cardiac arrest compared with drug treatment in patients with atrial fibrillation (AF) in a large...

Third of patients with lower GI cancers face delays

A third of patients in England with lower gastrointestinal cancers are facing delayed treatment, while figures show that NHS performance against treatment time targets has fallen to an all time...

Medication Treatment of Delirium: How Far Have We Come?

A sophisticated analysis suggests two useful interventions, but clinicians should consider simple environmental interventions before adding yet another medication.

MIT researchers devise new way to reduce burden of tuberculosis treatment

MIT said about one third of world’s population is affected by the deadly infectious disease and one of the main reasons TB is so pervasive is that the The post MIT researchers devise new way to reduce burden of tuberculosis treatment appeared first on Compelo Medical Devices - Latest industry news and analysis.

Diagnostics Data Analytics Company Diaceutics to List on London Stock Exchange

Company seeking £53M IPO on London Stock Exchange junior market, AIM (Alternative Investment Market) Diaceutics expects the addressable market for its specific services to grow to US$2.5BN by 2023 Diaceutics plc, a revenue-generating and profitable diagnostics data analytics and implementation services company which ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks